Importance of UDP-glucuronosyltransferase 1A1*6 for irinotecan toxicities in Japanese cancer patients

Cancer Letters

Volumn 261, Issue 2, 2008, Pages 165-171

  Sai, Kimie ^a   Saito, Yoshiro ^a   Sakamoto, Hiromi ^b   Shirao, Kuniaki ^c   Kurose, Koichi ^a   Saeki, Mayumi ^a   Ozawa, Shogo ^a   Kaniwa, Nahoko ^a   Hirohashi, Setsuo ^b   Saijo, Nagahiro ^d   Sawada, Jun ichi ^a   Yoshida, Teruhiko ^b  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Irinotecan; Pharmacogenetics; SN 38; UGT1A1

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; FLUOROURACIL; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MITOMYCIN C;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ASSESSMENT; COLON CANCER; CONTINUOUS INFUSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; INCIDENCE; JAPANESE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ASIAN CONTINENTAL ANCESTRY GROUP; BILIRUBIN; CAMPTOTHECIN; FEMALE; GENOTYPE; GLUCURONOSYLTRANSFERASE; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES;

EID: 39149141390     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.11.009     Document Type: Article

References (23)

1. Slatter J.G., Su P., Sams J.P., Schaaf L.J., and Wienkers L.C. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab. Dispos. 25 (1997) 1157-1164
2. Iyer L., King C.D., Whitington P.F., Green M.D., Roy S.K., Tephly T.R., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 15 (1998) 847-854
3. Ciotti M., Basu N., Brangi M., and Owens I.S. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem. Biophys. Res. Commun. 260 (1999) 199-202
4. Gagne J.F., Montminy V., Belanger P., Journault K., Gaucher G., and Guillemette C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol. 62 (2002) 608-617
5. Oguri T., Takahashi T., Miyazaki M., Isobe T., Kohno N., Mackenzie P.I., et al. UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers. Anticancer Res. 24 (2004) 2893-2896
6. Hanioka N., Ozawa S., Jinno H., Ando M., Saito Y., and Sawada J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 31 (2001) 687-699
7. de Forni M., Bugat R., Chabot G.G., Culine S., Extra J.M., Gouyette A., et al. Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res. 54 (1994) 4347-4354
8. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E., and Ratain M.J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54 (1994) 3723-3725
9. Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 60 (2000) 6921-6926
10. *28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2 (2002) 43-47
11. Innocenti F., Undevia S.D., Iyer L., Chen P.X., Das S., Kocherginsky M., et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22 (2004) 1382-1388
12. Marcuello E., Altes A., Menoyo A., Del Rio E., Gomez-Pardo M., and Baiget M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91 (2004) 678-682
13. Rouits E., Boisdron-Celle M., Dumont A., Guerin O., Morel A., and Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10 (2004) 5151-5159
14. Kaniwa N., Kurose K., Jinno H., Tanaka-Kagawa T., Saito Y., Saeki M., et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American. Drug Metab. Dispos. 33 (2005) 458-465
15. Sai K., Saeki M., Saito Y., Ozawa S., Katori N., Jinno H., et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther. 75 (2004) 501-515
16. Araki K., Fujita K., Ando Y., Nagashima F., Yamamoto W., Endo H., et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci. 97 (2006) 1255-1259
17. *28. Pharmacogenet. Genomics 17 (2007) 497-504
18. Han J.Y., Lim H.S., Shin E.S., Yoo Y.K., Park Y.H., Lee J.E., et al. Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin. J. Clin. Oncol. 24 (2006) 2237-2244
19. Saeki M., Saito Y., Jinno H., Tohkin M., Kurose K., Kaniwa N., et al. Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. Clin. Chem. 49 (2003) 1182-1185
20. Saeki M., Saito Y., Sai K., Maekawa K., Kaniwa N., Sawada J., et al. A combinatorial haplotype of the UDP-glucuronosyltransferase 1A1 gene (#60-#IB) increases total bilirubin concentrations in Japanese volunteers. Clin. Chem. 53 (2007) 356-358
21. Noguchi M., Furuya S., Takeuchi T., and Hirohashi S. Modified formalin and methanol fixation methods for molecular biological and morphological analyses. Pathol. Int. 47 (1997) 685-691
22. Otsuji S., Mizuno K., Ito S., Kawahara S., and Kai M. A new enzymatic approach for estimating total and direct bilirubin. Clin. Biochem. 21 (1988) 33-38
23. Kitagawa C., Ando M., Ando Y., Sekido Y., Wakai K., Imaizumi K., et al. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet. Genomics 15 (2005) 35-41